Nov. 12 (Bloomberg) -- GlaxoSmithKline Plc’s experimental drug darapladib didn’t reduce the risk of heart attack or stroke in a late-stage study, the second time a clinical trial of the medicine has disappointed investors.
The test results mean the drug failed the main goal of the study known as Stability, which tracked more than 15,000 patients suffering from chronic coronary heart disease, London-based Glaxo said in a statement today. The stock fell the most in three weeks.
Human Genome Sciences Inc., which Glaxo bought last year for $3 billion, originally developed darapladib. The treatment was intended to help rid patients with heart disease of the plaque that builds up in their arteries. After the drug didn’t show enough plaque-busting potential in a mid-stage study five years ago, Glaxo decided to test its ability to prevent pieces of plaque from rupturing and causing potentially fatal blood clots, but expectations of success were low.
“It is not surprising that darapladib did not show a benefit,” Andrew Whitney, an analyst at UBS AG, said in a report to investors today. Whitney estimated the drug only had a 20 percent chance of clinical success in the new indication. “Today’s data point is more removal of a potential positive, rather than a real negative.”
Glaxo fell as much as 1.7 percent, the steepest intraday decline since Oct. 23, and was trading down 1.1 percent at 1,632.5 pence at 3:17 p.m. in London. That pared the stock’s gain this year to 22 percent, valuing the drugmaker at 79.3 billion pounds ($127 billion).
The failure follows disappointing results from another high-risk experimental drug, MAGE-A3, which didn’t help skin-cancer patients in a late-stage trial. The back-to-back failures call into question Glaxo’s decision-making when it comes to advancing medicines into final-stage testing, Tim Anderson, an analyst at Sanford C. Bernstein & Co. in New York, said in a note to investors today.
“It has been a red flag that, with both candidates, no other pharmaceutical companies were chasing the same dream” in terms of the drugs’ biological targets, Anderson said.
Glaxo said it will review the test data, which indicated that some subgroups of patients benefited from treatment with darapladib, and will await the results of a second late-stage study in acute coronary syndrome before deciding what to do.
The main goal in the study described today was a measure of time to first occurrence of any major cardiovascular event, which included heart attack, stroke and death, Glaxo said. Patients in the test, which tracked participants since December 2008, took darapladib or a placebo in addition to a cholesterol-lowering statin.
The drug was developed for patients who aren’t helped enough by statins, a class of medicines that includes Pfizer Inc.’s Lipitor and AstraZeneca Plc’s Crestor. About 12 million people in the U.S. and 21 million worldwide don’t achieve the recommended reduction in low-density lipoprotein cholesterol with statins, according to a presentation last year by Sanofi, which is also developing a new drug to reduce cholesterol.
Heart disease and stroke are the two biggest causes of death worldwide, accounting for almost 22 percent of deaths in 2011, according to the Geneva-based World Health Organization. The LDL form of cholesterol only comes from eating animal products, and it raises the risk of the two illnesses by clogging arteries, according to the American Heart Association.
To contact the reporter on this story: Makiko Kitamura in London at email@example.com
To contact the editor responsible for this story: Phil Serafino at firstname.lastname@example.org